Minoryx and Neuraxpharm have agreed a strategic alliance to provide a new therapy for rare CNS disease patients in Europe.
The companies have entered into a license agreement for the European rights to leriglitazone, currently under European Medicines Agency (EMA) review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD).
Minoryx has granted Neuraxpharm exclusive European rights to leriglitazone, a novel, brain penetrant and selective PPAR gamma agonist. Minoryx retains full rights in the US and the rest of world, excluding already partnered China.
As part of the agreement, Neuraxpharm has agreed to pay Minoryx an upfront payment in addition to milestone payments and development funding totalling up to €258 million.
Leriglitazone will be the first approved treatment for adult male patients with X-ALD if it is approved by the EMA. Minoryx and Neuraxpharm will continue the development of leriglitazone for additional X-ALD patient populations and other orphan indications.